South Korea · Delayed Price · Currency is KRW Genolution Statistics
Total Valuation
Genolution has a market cap or net worth of KRW 32.66 billion. The enterprise value is 28.25 billion.
| Market Cap | 32.66B |
| Enterprise Value | 28.25B |
Important Dates
The last earnings date was Friday, April 3, 2026.
| Earnings Date | Apr 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genolution has 18.07 million shares outstanding. The number of shares has increased by 0.12% in one year.
| Current Share Class | 18.07M |
| Shares Outstanding | 18.07M |
| Shares Change (YoY) | +0.12% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 19.68% |
| Owned by Institutions (%) | n/a |
| Float | 12.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.47 |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.43 |
| EV / Sales | 3.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.87 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.35.
| Current Ratio | 1.30 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.29 |
| Interest Coverage | -9.87 |
Financial Efficiency
Return on equity (ROE) is -16.98% and return on invested capital (ROIC) is -13.15%.
| Return on Equity (ROE) | -16.98% |
| Return on Assets (ROA) | -5.39% |
| Return on Invested Capital (ROIC) | -13.15% |
| Return on Capital Employed (ROCE) | -12.68% |
| Weighted Average Cost of Capital (WACC) | 4.02% |
| Revenue Per Employee | 125.39M |
| Profits Per Employee | -155.23M |
| Employee Count | 75 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 2.28 |
Taxes
In the past 12 months, Genolution has paid 3.90 million in taxes.
| Income Tax | 3.90M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.65% in the last 52 weeks. The beta is 0.11, so Genolution's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -21.65% |
| 50-Day Moving Average | 1,808.52 |
| 200-Day Moving Average | 2,115.56 |
| Relative Strength Index (RSI) | 51.84 |
| Average Volume (20 Days) | 75,811 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genolution had revenue of KRW 9.40 billion and -11.64 billion in losses. Loss per share was -644.00.
| Revenue | 9.40B |
| Gross Profit | 3.44B |
| Operating Income | -8.64B |
| Pretax Income | -12.59B |
| Net Income | -11.64B |
| EBITDA | -6.28B |
| EBIT | -8.64B |
| Loss Per Share | -644.00 |
Balance Sheet
The company has 27.92 billion in cash and 24.03 billion in debt, with a net cash position of 3.89 billion or 215.07 per share.
| Cash & Cash Equivalents | 27.92B |
| Total Debt | 24.03B |
| Net Cash | 3.89B |
| Net Cash Per Share | 215.07 |
| Equity (Book Value) | 67.88B |
| Book Value Per Share | 3,774.89 |
| Working Capital | 7.67B |
Cash Flow
In the last 12 months, operating cash flow was -7.01 billion and capital expenditures -296.30 million, giving a free cash flow of -7.31 billion.
| Operating Cash Flow | -7.01B |
| Capital Expenditures | -296.30M |
| Depreciation & Amortization | 2.36B |
| Net Borrowing | -337.92M |
| Free Cash Flow | -7.31B |
| FCF Per Share | -404.50 |
Margins
Gross margin is 36.60%, with operating and profit margins of -91.89% and -123.80%.
| Gross Margin | 36.60% |
| Operating Margin | -91.89% |
| Pretax Margin | -133.83% |
| Profit Margin | -123.80% |
| EBITDA Margin | -66.76% |
| EBIT Margin | -91.89% |
| FCF Margin | n/a |
Dividends & Yields
Genolution does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.12% |
| Shareholder Yield | -0.12% |
| Earnings Yield | -35.64% |
| FCF Yield | -22.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 19, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Apr 19, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Genolution has an Altman Z-Score of 1.54 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.54 |
| Piotroski F-Score | 3 |